semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  End Stage Renal Failure on Dialysis Participants will be selected from the Vancouver Community Dialysis Unit. The for participant selection will be: 1. Dialysing for greater than six months to ensure access patency, viability, and stability; 2. Undergoing thrice weekly, four-hour dialysis sessions for uniform dialysis duration; 3. Dialysing with an arteriovenous fistula, either brachio-cephalic or radio-cephalic, to control variances in blood flow rates related to vascular access; 4. Dialysing with 15g needles as organization policy restricts greater flow rates with smaller needle gauge; 5. Dialysing with a dialysate flow (Qd) of 500 mL/min to reduce the possibility of clearance being attributable to differences in Qd; 6. Maintaining transonic vascular access flows of >600 mL/min for the past 6 months, per Kidney Dialysis Outcomes Quality Initiative (KDOQI) (NKF, 2006) minimum flow guidelines, to ensure access patency  Patients who speak a language other than English, Cantonese, Mandarin, or Punjabi will be excluded due to funding constraints for providing translated informed consent documents. Informed consent documents will only be available in the languages listed above, which are the most common languages spoken/read at the dialysis unit. Patients who dialyse with a central venous catheter, arteriovenous graft, or femoral arteriovenous fistula will not be invited to participate due to potential confounding from known differences in access flows and vessel quality that may impact clearance values. Patients who are involved in any other research study that would interfere with their dialysis treatment would be excluded from the study. Patients who are hemodynamically unstable (e.g.: frequent 'crashing' due to severe hypotension) will be excluded due to the instability this would pose on achieving their prescribed dialysis time (e.g.: if they crash, they may be taken off dialysis early) and resulting data
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Postpartum Haemorrhage Parturients aged more than 18 years old 2. American Society of Anesthesiologists (ASA) physical status class 1 to 3 3. Parturients planned for caesarean sections (both emergency and elective) under regional anaesthesia 4. Parturients who have increased risks of bleeding during caesarean deliveries as follows: Moderate Risk for Bleeding Induction of labour Prolonged labour >12 hours Large baby > 4kg Pyrexia in labour Age > 40 years (not multiparous) Obesity (BMI >35) Anaemia (Hb < 9g/dl) Multigravida Previous history of PPH  Parturients who have an urgent/emergency indication for caesarean sections where timing of the operation may be critical in determining the maternal and/or foetal outcomes 2. Patients who are planned for caesarean sections under general anaesthesia 3. Patients who are already clinically bleeding prior to surgery 4. Parturients who received blood transfusion within 48 hours prior to the caesarean section 5. Patients with known allergy to tranexamic acid 6. Patients with clear contraindications for tranexamic acid (e.g. thromboembolic event, history of convulsions) 7. Patients with severe renal failure with creatinine clearance <10
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Diabetes Mellitus, Type 2 Between 18 and 65 years of age Healthy Have venous access sufficient to allow for intravenous (IV) infusion and blood sampling as per protocol Subject's body mass index (BMI) is >=18 kilogram (kg)/meter(m)^2 and <=30 kg/m^2 Male or Female: if she is not pregnant (as confirmed by a test at screening and at other timepoints), not lactating, and at least one of the following conditions applies: a) cannot bear children OR b) agrees to follow contraception requirements defined in the protocol Capable of giving signed informed consent  Alanine aminotransferase (ALT) >1.5x Upper limit of normal (ULN) Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) Current or chronic history of liver disease, or known hepatic or biliary abnormalities QT interval corrected for heart rate according to Fridericia's formula (QTcF) > 450 milliseconds (msec) Systolic blood pressure is >=140 millimetre (mm) mercury (Hg) at Screening Diastolic blood pressure is >=90 mm Hg at Screening Heart rate is >100 beats/min at Screening Fasting triglyceride level >300 milligram/decilitre at Screening History of cholecystitis or other gallbladder disease History of gallstones, biliary motility dysfunction, or any condition rendering the subject unsuitable for ultrasonography assessments
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Resident Education and Assessment of Difficult and High Acuity Scenarios That Focus on Cardiac Anesthesia Resident physicians who have completed at least one month of cardiac rotation are included.This high fidelity simulation lab course if offerred to every resident that meets the criteria.This is a part of their educational activity.At the beginning of the course they are given the option to participate in the survey.If they do not wish to participate in the survey it will not affect their education.Participitaion in the survey is purely voluntary  Resident physicians that did not wish to participate in filling out the survey or not able to fill out the survey
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cystic Fibrosis Parents of adolescents (aged 11 to 16) with Cystic Fibrosis Self reported difficulties with their child's treatment adherence  Families already receiving psychological support from specialist Cystic Fibrosis clinical psychologists Parents requiring reading assistance who do not have anyone to help them Families where the parent/ child is currently being treated for a mental health difficulty
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 35.0-60.0,  Type 2 Diabetes Overweight Obesity Masked Hypertension Male or female, age between 35-60 years old 2. Type 2 diabetes 3. 24kg/m²≤BMI≤32kg/m², or WC≥90cm for male and WC≥85cm for female 4. Grade 1 hypertension or masked hypertension diagnosed via 24-h ambulatory blood pressure monitoring (daytime blood pressure load 50%≥135/85 mmHg, night time blood pressure load 50%≥125/75 mmHg or 24h blood pressure load 50%≥130/80 mmHg）  Type 2 diabetes with serious complications, such as diabetic neuropathy, diabetic retinopathy, stage IV diabetic nephropathy, or acute diabetic complications. 2. Type 1 diabetes. 3. Diagnosed moderate to severe sleep apnea syndrome(SAS). 4. Grade 2 or Grade 3 hypertension. 5. Triglyceride≥5.65mmol/L 6. History of cardio-cerebral vascular events such as congestive heart failure, myocardial infarction or stroke within 3 months. 7. Hypohepatia (AST or AST is twice higher than the upper limit) or history of hepatitis or cirrhosis, hepatic encephalopathy. 8. Renal insufficiency ( serum creatinine is 1.5 times higher than the upper limit) or history of dialysis and nephritic syndrome. 9. Chronic obstructive pulmonary disease (COPD), chronic respiratory failure or hyoxemia. 10. Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine addiction. 11. Fertile woman without contraceptives. 12. Any surgical or medical conditions that significantly influence absorption, distribution, metabolism or excretion of the intervention drugs. 13. Allergic to or have contraindication to the intervention drugs
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Low Back Pain additional for asymptomatic healthy adults no existing LBP and no LBP in the past year additional for patient participants existing LBP near the L5-S1 level with an average pain intensity score ≥ 2/10 (numeric pain rating scale of 0-10, 0 being no pain, 10 being unbearable pain)  previous low back surgery systemic joint disease (e.g. rheumatoid arthritis) cancer of the lower quadrant neurological disorders allergic reaction to ultrasound gel, or inability to obtain testing positions (prone lying)
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Athletes Healthy The subject must have given his/her informed and signed consent The subject must be insured or beneficiary of a health insurance plan The subject is participating in the 2015 Mont-Blanc Ultra Trail and has no contra-indication for ultra-trail activities  The subject is participating in another study The subject is in an period determined by a previous study The subject is under judicial protection, under tutorship or curatorship The subject refuses to sign the consent It is impossible to correctly inform the subject The subject is pregnant or breastfeeding The subject will be excluded from the study in case of early drop out (before 15 km of trail)
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cirrhosis Patients who develop new onset feed intolerance to enteral nutrition  Any patient with current or past surgical abdomen including mechanical obstruction, mesenteric ischemia, perforation or requiring abdominal surgery. 2. Patients receiving enteral nutrition through gastrostomy or jejunostomy. 3. Patients in whom, prokinetics are contraindicated or are allergic to the same. 4. Patients who received prokinetic more than one day prior to the start of enteral feeding. 5. Patients with uncontrolled sepsis with DIC. 6. Requirement of two or more vasopressors. 7. Organ failure requiring high inotropic support. 8. Advanced cardiopulmonary disease, with prior history of arrhythmias, structural heart disease. 9. History of traumatic brain injury, raised intracranial pressure, history of myasthenia gravis. 10. Endocronolgic illnesses: Hypothyroidism, hypoparathyroidism 11. Connective tissue diseases (systemic sclerosis, dermatomyositis or polymyositis, systemic lupus erythematosis, amyloidosis). 12. Known case of diabetes with diabetic gastroparesis 13. Pregnancy 14. Patients or concerned family member who fail to give consent for study enrollment 15. Age less than 18 years and more than 70 years
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Acute Upper Gastrointestinal Bleeding patients with overt signs of upper gastrointestinal bleeding (hematemesis, melena and/or circulatory instability) documented bleeding (Forrest I) from a non-variceal upper gastrointestinal source (gastro-duodenal ulcers, Mallory Weiss tear, cancers, Dieulafoy's and other vascular lesions) at endoscopy  without a full informed consent from the patient or his next of kin Age <18 years Pregnant Lactating women
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Abdominal Pain Diarrhea Hematochezia Patients who repeatedly have the symptom such as abdominal pain, diarrhea, hematochezia and so on, or Patients who volunteer to the colonoscopy screening  Dysphagia or swallowing disorder Congestive heart failure Renal insufficiency Prior major abdominal surgery of the gastrointestinal tract Known or suspected bowel obstruction Presence of a cardiac pacemaker or other implanted electromedical devices Allergy or contraindication to the medications used in the study
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Cigarette Smoking generally healthy (i.e. ambulatory, not currently sick) interest in quitting smoking smoking of at least 5 cig/day of a brand delivering ≥ 0.5 mg nicotine (FTC method) for > 1 year an expired carbon monoxide concentration of at least 10 ppm (to confirm inhalation) or urinary cotinine > 1000 ng/mL to confirm daily smoking (NicAlert=6)  inability to attend all required experimental sessions desire to quit smoking prior to the study quit date a quit attempt resulting in greater than 3 days of abstinence in the past 30 days report of significant health problems including but not restricted to (e.g. chronic hypertension, emphysema, seizure disorder, history of significant heart problems) unstable psychiatric conditions (any significant change in psychiatric symptoms during the past 3 months as determined by the study physician) schizophrenia and schizoaffective disorder psychiatric medication changes (e.g. new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms use of other tobacco products or e-cigarettes more than 9 days in the past 30 days current alcohol or drug abuse use of illegal drugs (excluding marijuana) or drugs without a valid prescription as measured by urine drug screen
Patient description: The patient is a 57-year-old man with abdominal pain and vomiting. The pain started gradually about 20 hours ago in the epigastric and periumbilical regions, radiating to his back. He drinks around 60 units of alcohol per week and smokes 22 cigarettes per day. He is healthy with no history of allergies or using any medications. His family history is positive for type 2 diabetes (his father and sister). He lives alone and has no children. The abdomen is tender and soft. His bowel sounds are normal. His heart rate is 115/min and blood pressure 110/75 mmHg. The lab results are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glc level of 15. Cross-sectional imaging was negative for obstructive pancreatitis.

Clinical trial eligibility criteria: eligible ages (years): 40.0-69.0,  Prostate Cancer Prostate Biopsy Genetic Counselling Genetic Markers Men with either: 1. A positive family history of PrCa defined as Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age 2. Of African or Caribbean ancestry defined as: Both parents and all 4 grandparents from that origin Age 40 years WHO performance status 02 (see Appendix A) Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow up schedule  Previous cancer with a life expectancy of less than five years Previous PrCa Negative biopsy within one year before recruitment Comorbidities making prostate biopsy risk unacceptable (Warfarin or Clopidogrel) Contraindications to having an MRI (pacemakers, aneurysm clips, claustrophobia)